Applied therapeutics to present baseline data on the phase 3 arise-hf study in diabetic cardiomyopathy at the 2023 annual meeting of the american diabetes association

New york, june 22, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple presentations on at-001 (caficrestat) and the arise-hf phase 3 study in diabetic cardiomyopathy at the 2023 annual meeting of the american diabetes association to take place june 23 - 26 in san diego, california.
APLT Ratings Summary
APLT Quant Ranking